Physician profile
Colin Ray
NPI 1194219279
$768.38
in general payments reported to CMS, 2019-2025
18 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.68 · 2022: $26.50 · 2023: $52.03 · 2024: $247 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $84.88 | 2023-2025 | Freestyle Libre 3 |
| Organogenesis INC. | $77.80 | 2024 | Puraply Wound Matrix |
| Abbvie INC. | $76.03 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.26 | 2023-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $45.19 | 2024-2025 | Veozah |
| Amgen INC. | $44.73 | 2022-2024 | Otezla, Repatha |
| Dynavax Technologies Corporation | $37.92 | 2024-2025 | Heplisav-B |
| Lilly USA, LLC | $35.27 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $31.65 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $30.11 | 2025 | |
| Sanofi-Aventis U.S. LLC | $29.71 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.29 | 2025 | |
| Axsome Therapeutics, INC. | $23.82 | 2025 | Auvelity |
| Corium, LLC | $23.13 | 2025 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.09 | 2025 | Xifaxan |
| Eisai INC. | $14.72 | 2024 | |
| Lundbeck LLC | $14.58 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.